Overview

Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma

Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of dose reduced postoperative radiotherapy combined with Anlotinib for patients of soft tissue sarcoma
Phase:
Phase 2
Details
Lead Sponsor:
Ruijin Hospital